New combo therapy aims to stop kidney damage in membranous nephropathy
NCT ID NCT00977977
First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 8 times
Summary
This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high protein in their urine will receive both drugs over 6 months, with follow-up for up to 2 years. The goal is to see if this combo can help more patients achieve remission and protect their kidneys from further damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab and cyclosporine
- What this could lead to
- If successful, this combination could offer a new treatment option for membranous nephropathy, potentially reducing protein in urine and protecting kidney function.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Both drugs suppress the immune system, which can increase infection risk and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
-
National Naval Medical Center
RECRUITINGBethesda, Maryland, 20889, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One infusion may keep childhood kidney disease at bay — a trial puts it to the test
- Genetic hunt for hidden causes of mysterious inflammatory diseases
- Teen diabetes study seeks to uncover hidden triggers of kidney damage
- Biopsy tolerance study ends early – what we know
- Kidney disease biobank aims to unlock new treatments
- Scientists hunt for genes behind kidney disease